Stryker's sales rose. Its market value fell back
Free, six mornings a week · Unsubscribe in one click
What the chart shows
Between 2021 and 2025 Stryker's annual revenue climbed from US$17.1bn to US$25.1bn, a rise in each of those years. Its market value has not kept pace. It was US$137.3bn at the end of 2024, US$134.4bn a year later and US$111.1bn on Friday.
Friday's 6.38% fall, to US$291.86 a share, followed a September quarter in which orthopaedics, the joint-implant division, grew 5.9% on an organic basis after 8.6% in the June quarter. Stryker also lowered its organic growth forecast for this year to between 6.5% and 7.0%, from 8.3% to 9.3% in July.
The story behind it
Stryker cut its growth forecast as orthopaedic sales slowed, and the shares fell 6.38% Read the edition →On the calendar
The US releases that move markets, in New Zealand and Australian time. Economic calendar →The numbers
Two scales, both from zero, in US$bn: revenue by year on the left; market value at each year end and on 30 October on the right. The value was 137.3 at the end of 2024.
| Revenue, US$bn | Market value, US$bn | |
|---|---|---|
| 2021 | 17.1 | 100.9 |
| 2022 | 18.4 | 92.5 |
| 2023 | 20.5 | 113.8 |
| 2024 | 22.6 | 137.3 |
| 2025 | 25.1 | 134.4 |
How we make these charts: one chart a day from a story in the edition, drawn from the figures the story names and checked against the sources named on the chart before it is published. General information only, not financial advice.
